Thyrocare Technologies Limited announced the outcome of its Board Meeting held on May 07, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. They also recommended a final dividend of ₹7.00 per equity share for FY2025-26, subject to shareholder approval at the AGM. The total dividend for the year, including interim dividend, aggregates to ₹9.33 per equity share (post bonus adjustment). The Board further approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a term of five consecutive years, commencing from the 26th AGM until the 31st AGM. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for FY2026-27. Key management changes were also approved: Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for five years from May 04, 2027. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 08, 2026. The Board noted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, both Non-Executive, Non-Independent Directors, effective close of business hours on May 07, 2026. Additionally, the company approved an investment not exceeding ₹5,50,00,000 in the equity shares of its wholly-owned subsidiary, Think Health Diagnostics Private Limited. The Memorandum of Association (MOA) of the company will be altered, subject to shareholder approval, to align with the Companies Act, 2013, and broaden the scope of activities within the healthcare and diagnostics ecosystem. The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM.
